Also referenced as: RT, Triple incretin agonist, GLP-1/GIP/glucagon receptor triagonist
A literature-led overview of GLP-3 (RT) — what has actually been measured in the published record, what remains unknown, and how research-grade material is characterised.
5 min read · Literature review · Updated 2026
Research-grade GLP-3 (RT) vials — ≥99% HPLC purity, lot-matched COA on request, from $55.99.
Shop GLP-3 (RT)A single-molecule triple agonist studied in published literature at the GLP-1, GIP and glucagon receptors, most often used as a high-potency incretin reference standard in metabolic assay work.
Research material is supplied as a lyophilised powder in a sealed vial, reconstituted with bacteriostatic water immediately before use and characterised by reverse-phase HPLC with identity confirmed by mass spectrometry. The published record for GLP-3 (RT) is dominated by published clinical and preclinical sources, which is the most important caveat when reading any summary of its reported effects.
The areas below summarise what published work has actually measured. Each is an observation reported in the cited literature — not a claimed outcome, and not a statement of efficacy in humans.
Metabolic signalling research
Published phase 2 literature has investigated triple incretin receptor engagement and its relationship to body-weight and glycaemic endpoints in enrolled human cohorts.
Energy expenditure pathway research
Glucagon-receptor engagement has been investigated preclinically for its association with hepatic substrate handling and thermogenic signalling.
Mechanistic descriptions of GLP-3 (RT) in the literature centre on the pathways below. Pathway attributions should be read as proposed rather than settled.
Triple incretin receptor agonism
Reported to bind and activate GLP-1, GIP and glucagon receptors, all class B G-protein-coupled receptors signalling largely through Gs/cAMP. Pathway noted in the literature: GLP-1R / GIPR / GCGR → Gs → adenylyl cyclase → cAMP → PKA.
Fatty-acid acylation and half-life
A lipid side chain is described in the literature as promoting albumin binding, which is associated with extended plasma residence in reported pharmacokinetic work. Pathway noted in the literature: Albumin binding / reduced renal clearance.
Because controlled human data for this compound class are still accumulating, reported safety signals should be read as literature observations only and do not establish safety for human use.
Reported observations in the available literature include: Gastrointestinal events were the most frequently reported adverse events in published trial literature; Dose-related tolerability signals reported during titration phases. These are reports from the study conditions described, not an established adverse-event profile.
Open data gaps: long-term safety, use outside supervised clinical trial settings. Peptide Lounge does not publish dosing or administration guidance for any compound, and this material is not for human or veterinary use.
Every GLP-3 (RT) lot is released at ≥99% purity by RP-HPLC with identity confirmed by ESI-MS, and a lot-matched certificate of analysis is available on request rather than a generic sample document.
Vials ship lyophilised and sealed, and are stable at ambient temperature during transit. Store unreconstituted vials refrigerated and protected from light; once reconstituted, keep refrigerated and treat the solution as short-dated. Experimental concentrations must be determined by the researcher from the peer-reviewed literature under their own institutional protocol.
GLP-3 (RT) is stocked as single-compound vials in 10mg, 20mg, 30mg, 60mg, with volume pricing applied automatically to multi-vial orders. Free bacteriostatic water and research supplies are included on qualifying orders.
Published work describes metabolic signalling research, energy expenditure pathway research. Some of this record includes human data, but findings should still be read in the context of each study's design.
Reported observations include Gastrointestinal events were the most frequently reported adverse events in published trial literature; Dose-related tolerability signals reported during titration phases. Beyond these, long-term safety, use outside supervised clinical trial settings remain open.
No. GLP-3 (RT) supplied by Peptide Lounge is a laboratory reagent for in-vitro and laboratory research only. It is not an approved drug and is not for human or veterinary use.
Store lyophilised vials refrigerated and protected from light. Reconstitute with bacteriostatic water immediately before use and keep the resulting solution refrigerated. Vials remain stable at ambient temperature during shipping.
Request the lot-matched certificate of analysis for the batch you received. It reports RP-HPLC purity (≥99%) and ESI-MS identity confirmation for that specific lot.
Published phase 2 literature has investigated triple incretin receptor engagement and its relationship to body-weight and glycaemic endpoints in enrolled human cohorts.
Glucagon-receptor engagement has been investigated preclinically for its association with hepatic substrate handling and thermogenic signalling.
Reported to bind and activate GLP-1, GIP and glucagon receptors, all class B G-protein-coupled receptors signalling largely through Gs/cAMP.
GLP-1R / GIPR / GCGR → Gs → adenylyl cyclase → cAMP → PKA
A lipid side chain is described in the literature as promoting albumin binding, which is associated with extended plasma residence in reported pharmacokinetic work.
Albumin binding / reduced renal clearance
Jastreboff AM, Kaplan LM, Frías JP et al.
Randomised, double-blind, placebo-controlled phase 2 trial evaluating a triple hormone-receptor agonist across multiple dose arms.
Limitations: 48-week duration; Phase 2 sample size
View study (DOI 10.1056/NEJMoa2301972)Because controlled human data for this compound class are still accumulating, reported safety signals should be read as literature observations only and do not establish safety for human use.
Known data gaps: Long-term safety, Use outside supervised clinical trial settings.
For Research Use Only
All products listed are supplied strictly as laboratory reagents for in-vitro research and analytical work conducted by qualified professionals. They are not drugs, foods, cosmetics or medical devices, and must not be administered to humans or animals. No product on this site is approved by the FDA for human use.
Research Use Only: Products are sold strictly for laboratory research and educational purposes only. Not for human consumption, veterinary use, food use, cosmetic use, or therapeutic application. Products are not intended to diagnose, treat, cure, or prevent any disease.
